Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer
- PMID: 17293390
- PMCID: PMC1972421
- DOI: 10.1136/jcp.2006.043356
Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer
Conflict of interest statement
Competing interests: none declared.
References
-
- Gong Y, Gilcrease M, Sneige N. Reliability of chromogenic in situ hybridization for detecting HER‐2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol 2005181015–1021. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous